910 related articles for article (PubMed ID: 17970613)
1. The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition.
Atlas SA
J Manag Care Pharm; 2007 Oct; 13(8 Suppl B):9-20. PubMed ID: 17970613
[TBL] [Abstract][Full Text] [Related]
2. Hypertension: renin-angiotensin-aldosterone system alterations.
Te Riet L; van Esch JH; Roks AJ; van den Meiracker AH; Danser AH
Circ Res; 2015 Mar; 116(6):960-75. PubMed ID: 25767283
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of the renin angiotensin aldosterone system: focus on aliskiren.
Rao MS
J Assoc Physicians India; 2010 Feb; 58():102-8. PubMed ID: 20653151
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution?
Athyros VG; Mikhailidis DP; Kakafika AI; Tziomalos K; Karagiannis A
Expert Opin Pharmacother; 2007 Apr; 8(5):529-35. PubMed ID: 17376010
[TBL] [Abstract][Full Text] [Related]
5. Optimal antagonism of the Renin-Angiotensin-aldosterone system: do we need dual or triple therapy?
Werner C; Pöss J; Böhm M
Drugs; 2010 Jul; 70(10):1215-30. PubMed ID: 20568830
[TBL] [Abstract][Full Text] [Related]
6. Beta-adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin-aldosterone system in normotensive and hypertensive subjects.
Blumenfeld JD; Sealey JE; Mann SJ; Bragat A; Marion R; Pecker MS; Sotelo J; August P; Pickering TG; Laragh JH
Am J Hypertens; 1999 May; 12(5):451-9. PubMed ID: 10342782
[TBL] [Abstract][Full Text] [Related]
7. Addressing the theoretical and clinical advantages of combination therapy with inhibitors of the renin-angiotensin-aldosterone system: antihypertensive effects and benefits beyond BP control.
Ferrario CM
Life Sci; 2010 Feb; 86(9-10):289-99. PubMed ID: 19958778
[TBL] [Abstract][Full Text] [Related]
8. Aliskiren and valsartan combination therapy for the management of hypertension.
Epstein BJ
Vasc Health Risk Manag; 2010 Sep; 6():711-22. PubMed ID: 20859542
[TBL] [Abstract][Full Text] [Related]
9. Dual blockade of the renin-angiotensin-aldosterone system: beyond the ACE inhibitor and angiotensin-II receptor blocker combination.
Bomback AS; Toto R
Am J Hypertens; 2009 Oct; 22(10):1032-40. PubMed ID: 19661925
[TBL] [Abstract][Full Text] [Related]
10. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
11. Is aliskiren superior to inhibitors of angiotensin-converting enzyme and angiotensin receptor blockers in renin-angiotensin system blockade?
Gerc V; Buksa M; Loza V; Kulic M
Med Arh; 2009; 63(6):343-9. PubMed ID: 20380117
[TBL] [Abstract][Full Text] [Related]
12. [The future of renin inhibition].
Uresin AY; Baran E
Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 7():32-8. PubMed ID: 20019475
[TBL] [Abstract][Full Text] [Related]
13. Limitations of angiotensin inhibition.
Nobakht N; Kamgar M; Rastogi A; Schrier RW
Nat Rev Nephrol; 2011 Jun; 7(6):356-9. PubMed ID: 21502972
[TBL] [Abstract][Full Text] [Related]
14. [How I treat... by optimizing the blockade of the renin-angiotensin-aldosterone system].
Schleich F; Krzesinski JM; Piérard L; Scheen AJ
Rev Med Liege; 2008 Apr; 63(4):174-81. PubMed ID: 18575070
[TBL] [Abstract][Full Text] [Related]
15. [Oral inhibitors of renin and their potential use as therapeutic agents in treating hypertension].
Abassi Z; Armaly Z; Nakhoul F; Hoffman A
Harefuah; 2008 Jun; 147(6):536-42, 573. PubMed ID: 18693632
[TBL] [Abstract][Full Text] [Related]
16. Have the renin-angiotensin-aldosterone system perturbations in cardiovascular disease been exhausted?
Mansur SJ; Hage FG; Oparil S
Curr Cardiol Rep; 2010 Nov; 12(6):450-63. PubMed ID: 20827517
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Angiotensin receptor blockers in cardiovascular disease.
Maggioni AP
Cardiovasc Drugs Ther; 2006 Aug; 20(4):295-308. PubMed ID: 16915347
[TBL] [Abstract][Full Text] [Related]
18. Recent changes in the landscape of combination RAS blockade.
Epstein BJ; Smith SM; Choksi R
Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1373-84. PubMed ID: 19900020
[TBL] [Abstract][Full Text] [Related]
19. Current strategies to achieve further cardiac and renal protection through enhanced renin-angiotensin-aldosterone system inhibition.
Alfie J; Aparicio LS; Waisman GD
Rev Recent Clin Trials; 2011 May; 6(2):134-46. PubMed ID: 21241234
[TBL] [Abstract][Full Text] [Related]
20. Aliskiren: a new inhibitor of renin-angiotensin aldosterone system activity.
Dalla Vestra M; Simioni N; Masiero A
Minerva Endocrinol; 2009 Dec; 34(4):333-8. PubMed ID: 20046162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
